Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2025 ARTÍCULOS , VIENDO DEL 1561 AL 1575

Periventricular diffusivity reflects APOE ε4-modulated amyloid accumulation and cognitive impairment in the Alzheimer's disease continuum

Chen CL, Son SJ, Schweitzer N, Jin H, Li J, Wang L, Yang S, Hong CH, Roh HW, Park B, Choi JW, An YS, Seo SW, Cho YH, Hong S, Nam YJ, Minhas DS, Laymon CM, Stetten GD, Tudorascu DL, Aizenstein HJ, Wu M; Mayo Clinic Study of Aging.

Alzheimers Dement. 2025 Sep;21(9):e70659. doi: 10.1002/alz.70659.

Effects of intermittent theta-burst stimulation on cognition and glymphatic system activity in mild cognitive impairment and very mild Alzheimer's disease: a randomized controlled trial

Yang CC, Huang KY, Hsu JL, Hu CJ, Lu YH, Kuan YC.

J Neuroeng Rehabil. 2025 Sep 26;22(1):195. doi: 10.1186/s12984-025-01738-1.

Inhibition of FAM19A5 reverses synaptic loss and cognitive decline in mouse models of Alzheimer's disease

Kim HB, Yoo S, Kwak H, Ma SX, Kim R, Lee M, Ha N, Pyo S, Kwon SG, Cho EH, Lee SM, Jang J, Kim WK, Park HC, Baek M, Park Y, Park JY, Park JW, Hwang SW, Hwang JI, Seong JY.

Alzheimers Res Ther. 2025 Jul 21;17(1):168. doi: 10.1186/s13195-025-01813-8.

Investigation of patterns and associations of neuroinflammation in cognitive impairment

Gan R, Xie H, Zhao Z, Wu X, Wang R, Wu B, Chen Q, Jia Z.

Cereb Cortex. 2025 Feb 5;35(2):bhaf013. doi: 10.1093/cercor/bhaf013.

Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease

Devanarayan V, Donohue MC, Sperling RA, Johnson KA, Ye Y, Charil A, Doherty T, Tian L, Raman R, Aisen PS, Kramer LD, Irizarry MC, Dhadda S.

Alzheimers Dement. 2025 Sep;21(9):e70702. doi: 10.1002/alz.70702.

Computerized cognitive training enhances cognitive function in Alzheimer's disease by downregulating Ruminococcus-TMAO pathway

Zhang W, Song J, Zhong F, Yu W, Qin Z, Yang Z, Liu J, Wang X, Chen L, Lü W, Xing D, Liu J, Huang C, Wu J, Liu X, Yu W, Lü Y.

J Transl Med. 2025 Oct 24;23(1):1173. doi: 10.1186/s12967-025-07209-4.

Amyloid PET and clinical management in a diverse, cognitively impaired population: The New IDEAS Study

Windon CC, Gatsonis C, Carrillo MC, Romanoff J, Hanna L, Glavin E, Gareen I, Gutman R, Hillner BE, March A, O'Bryant S, Rissman RA, Siegel BA, Smith K, Whitmer RA, Weber CJ, Wilkins CH, Dilworth-Anderson P, Rabinovici GD.

Alzheimers Dement. 2025 Jul;21(7):e70504. doi: 10.1002/alz.70504.

Development and validation of a model to predict the progression of Alzheimer's disease

Chu C, Wang Y, L H Huynh A, Ng KW, Liu S, Ji G, Doecke J, Fripp J, Masters CL, Goudey B, Jin L, Pan Y.

Age Ageing. 2025 Jul 1;54(7):afaf198. doi: 10.1093/ageing/afaf198.

Eligibility for donanemab trial in a population-based study of cognitive aging

Jones KE, Aakre JA, Castillo AM, Ramanan VK, Kremers WK, Jack CR Jr, Vemuri P, Schwarz CG, Lowe VJ, Knopman DS, Petersen RC, Graff-Radford J, Vassilaki M.

J Prev Alzheimers Dis. 2025 Apr;12(4):100088. doi: 10.1016/j.tjpad.2025.100088. Epub 2025 Feb 17.

Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Trial: Genetic Resource for Precision Nutrition

Liu Y, Fowler H, Wang DD, Barnes LL, Cornelis MC.

Nutrients. 2025 Aug 4;17(15):2548. doi: 10.3390/nu17152548.

The effects of the Multicultural Healthy Diet on cognitive decline and Alzheimer's disease risk: a phase II randomized controlled trial in middle-aged adults

Mossavar-Rahmani Y, Hyun N, Hakun JG, Katz MJ, Pavlovic JM, Zetterberg H, Wang Z, Yang JB, Wylie-Rosett J, Hebert JR, Sliwinski MJ, Shaw PA.

Am J Clin Nutr. 2025 Jul;122(1):48-59. doi: 10.1016/j.ajcnut.2025.05.011. Epub 2025 May 22.

Retinal vascular alterations in cognitive impairment: A multicenter study in China

Shi Q, Ni A, Li K, Su W, Xie W, Zheng H, Wang M, Xiao Z, Wu W, Shi K, Zhang P, Yan B, Ding D, Kwok T, Zhao Q, Zhang J.

Alzheimers Dement. 2025 Feb;21(2):e14593. doi: 10.1002/alz.14593.

Japanese participant data from three gantenerumab trials in early Alzheimer's disease

Asada T, Thanasopoulou A, Delmar P, Wojtowicz J, Smith J, Yoshiyama Y, Yokoi K, Watanabe C, Isozaki M, Ozaki R, Ishida T, Tatsuda H, Tamaoka A.

Alzheimers Dement. 2025 Apr;21(4):e70192. doi: 10.1002/alz.70192.

Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study

Pascual-Lucas M, Lacosta AM, Montañés M, Canudas J, Loscos J, Monleón I, Allué JA, Sarasa L, Fandos N, Romero J, Sarasa M, Torres M, Whyms D, Terencio J, Piñol-Ripoll G, Boada M.

Alzheimers Dement. 2025 Oct;21(10):e70776. doi: 10.1002/alz.70776.

Gamma oscillation modulation for cognitive impairment: A systematic review

Bartolini E, Di Crosta A, La Malva P, Marin A, Ceccato I, Prete G, Mammarella N, Di Domenico A, Palumbo R.

J Alzheimers Dis. 2025 May;105(2):331-350. doi: 10.1177/13872877251328698. Epub 2025 Mar 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias